1 Biotech Stock Set to Rebound in 2026

For all the enthusiasm around GLP-1s, also known as weight-loss drugs, Novo Nordisk (NYSE: NVO) tumbled nearly 42% in 2025. The once hot stock was confounded by headwinds, including rivals making progress in the weight-loss arena and the emergence of cheaper generics.Fast-forward to 2026, and the stock is already shedding last year's bear market conditions. Shares of the maker of Wegovy are up 25% year to date. That's a new bull market and then some.This weight-loss leader is already rebounding and could extend that bullishness this yea. Image source: Getty ImagesContinue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool